Skip to main content
FutureChem Co., Ltd. logo

FutureChem Co., Ltd. — Investor Relations & Filings

Ticker · 220100 ISIN · KR7220100002 KO Manufacturing
Open in API
Filings indexed 312 across all filing types
Latest filing 2025-09-15 Legal Proceedings Report
Country KR South Korea
Listing KO 220100

About FutureChem Co., Ltd.

https://www.futurechem.co.kr/?language=…

FutureChem Co., Ltd. is a company specializing in the development and production of radiopharmaceuticals for diagnostic and therapeutic applications. The company's operations cover the manufacturing of radiopharmaceutical precursors, chemical compounds, synthesis reagents, and automated synthesis modules. Its product pipeline focuses on agents for the diagnosis and treatment of various cancers and neurological disorders, including Parkinson's disease. FutureChem supports the broader radiopharmaceutical field by providing both finished products and the essential chemical building blocks and equipment required for their synthesis. The company actively establishes global partnerships for clinical supply and commercial licensing of its technologies.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항(임상시험결과) (전립선암 치료용 [Lu177]Ludotadipep 방사성의약품 FC705 의 국내 2상 임상시험 결과 [임상시험결과보고서(Clinical Study Report, CSR) 수령])
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a 'Major Management Matter' (주요경영사항) concerning clinical trial results for a pharmaceutical product (FC705). It details the efficacy and safety results of a Phase 2 clinical trial. Since it is a formal regulatory disclosure of material information regarding company operations and clinical progress, it falls under the 'Regulatory Filings' category.
2025-09-15 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세저항성 전립선암 환자에서 [177Lu]루도타다이 펩의 유효성 및 안전성을 평가하기 위한 다기관, 공개, 무작위배정, 제3상 임상시험(임상시험 계획 승인))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (FutureChem) regarding the approval of a Phase 3 clinical trial by the Ministry of Food and Drug Safety. It is a formal disclosure of a material business event ('투자판단 관련 주요경영사항'). Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a standard regulatory disclosure of clinical trial status, it falls under the 'Regulatory Filings' category.
2025-09-04 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'FutureChem' covering the period from January 1, 2025, to June 30, 2025. It contains detailed corporate information, financial data, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement (849 characters) regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides the date, location, purpose, and mentions that IR materials will be distributed at the event and posted on the KRX KIND system. Since it is an announcement of an event and the availability of materials rather than the presentation itself, it falls under the category of a regulatory filing announcement.
2025-07-14 Korean
투자판단관련주요경영사항 (프로스타뷰([F18]플로라스타민)주사액 식품의약품안전처 신약 허가)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details the company's application for new drug approval (NDA) for 'Prostaview' to the Ministry of Food and Drug Safety (MFDS). Since this is a formal regulatory disclosure of a material business event (drug approval application) rather than a standalone report, financial statement, or presentation, it falls under the 'Regulatory Filings' category.
2025-07-10 Korean
투자판단관련주요경영사항(임상시험결과) ([F18]Florastamin 제3상 임상시험 결과보고서 수령)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure filed by FutureChem regarding the results of a Phase 3 clinical trial for their drug [F-18]Florastamin. It details the trial methodology, primary endpoints, statistical results, and safety data, and outlines future plans for regulatory submission. As this is a specific regulatory announcement regarding material business developments (clinical trial results) that does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2025-07-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.